Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer

▸ TREATMENT

A patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer responded to re-challenge with encorafenib and cetuximab combined with nivolumab after prior progression, suggesting this combination may offer renewed benefit in select cases. (Clinical Colorectal Cancer)